CAR T

For Applied DNA, new blood – and a shot in the arm

By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition. LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony Brook University and a patented method of isolating Invasive Circulating Tumor Cells in standard blood samples – spotting metastatic cells…


At LineaRX, putting the horsepower behind the CAR T

By GREGORY ZELLER // Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform. In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer. The tech comes from LineaRx Inc., a wholly owned subsidiary that officially spun off from Stony Brook-based Applied DNA Sciences in September. Noting…